Get the Stockscreener App
0.83
4.60%
-0.04
After Hours:
.85
0.02
+2.41%
Windtree Therapeutics Inc stock is traded at $0.83, with a volume of 78,167.
It is down -4.60% in the last 24 hours and down -29.66% over the past month.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
See More
Previous Close:
$0.87
Open:
$0.86
24h Volume:
78,167
Relative Volume:
0.01
Market Cap:
$3.02M
Revenue:
-
Net Income/Loss:
$-11.38M
P/E Ratio:
-0.0299
EPS:
-27.73
Net Cash Flow:
$-12.72M
1W Performance:
-2.23%
1M Performance:
-29.66%
6M Performance:
+74.70%
1Y Performance:
-81.96%
1-Day Range:
$0.8189
$0.8701
1-Week Range:
$0.8147
$0.9521
52-Week Range:
$0.0915
$14.75
Windtree Therapeutics Inc Stock (WINT) Company Profile
Name
Windtree Therapeutics Inc
Sector
Industry
Phone
(215) 488-9300
Address
2600 KELLY ROAD, WARRINGTON, PA
Compare WINT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WINT
Windtree Therapeutics Inc
|
0.83 | 3.02M | 0 | -11.38M | -12.72M | -27.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.38 | 110.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
584.99 | 59.13B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
561.75 | 34.75B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
283.40 | 33.69B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
225.77 | 25.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Windtree Therapeutics Inc Stock (WINT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-26-20 | Initiated | Ladenburg Thalmann | Buy |
Windtree Therapeutics Inc Stock (WINT) Latest News
WINDTREE THERAPEUTICS INC /DE/ SEC 10-Q Report - TradingView
Windtree Therapeutics (WINT) to Release Earnings on Wednesday - Defense World
WINT: Windtree Therapeutics Reveals Promising Data on Istaroxime - GuruFocus
Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025 - The Manila Times
Windtree Therapeutics Announces Positive Results on Istaroxime and SERCA2a Activator in Reducing Arrhythmias at ESC Heart Failure Congress - Nasdaq
Windtree Therapeutics Unveils U.S. Exclusivity Strategy for Istaroxime - MSN
Windtree Therapeutics Announces Plans to Acquire Multifamily Residential Property - MSN
Warrington-Based Windtree Therapeutics Buys Huston Apartment Complex - BUCKSCO.Today
Daily Progress: Windtree Therapeutics Inc (WINT) Drop -11.76, Closing at 0.90 - DWinneX
Windtree Therapeutics Secures Patent in Japan for Cancer Treatment Platform - MSN
Windtree Therapeutics (WINT) Eyes U.S. Exclusivity for Istaroxime | WINT Stock News - GuruFocus
Windtree Announces Istaroxime Exclusivity and Intellectual Prope - GuruFocus
Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US - The Manila Times
Windtree Therapeutics Announces Strategic Pathway for 7.5 Years of U.S. Exclusivity for Istaroxime in Cardiogenic Shock - Nasdaq
Windtree Secures 7.5-Year Exclusivity Strategy for Revolutionary Cardiogenic Shock Treatment - Stock Titan
Why biotech firm Windtree Therapeutics is buying a 436-unit apartment complex - The Business Journals
WINT’s Stock Market Adventure: -94.27% YTD Growth Amidst Volatility - investchronicle.com
Examining Windtree Therapeutics Inc (WINT) more closely is necessary - uspostnews.com
Market Resilience: Windtree Therapeutics Inc (WINT) Finishes Weak at 1.00, Down -14.53 - DWinneX
Windtree Therapeutics (WINT) Pursues Strategic Real Estate Acqui - GuruFocus
Windtree Therapeutics (WINT) Pursues Strategic Real Estate Acquisition | WINT Stock News - GuruFocus
Windtree Therapeutics Raises $2.5M in Private Placement - TipRanks
Windtree Announces Strategic Transaction to Drive Revenue Generation in Support of Ongoing Therapeutic Pipeline Development - The Manila Times
Windtree Therapeutics Reports 2024 Financial Results and Strategic Developments - MSN
Windtree Therapeutics announces board member resignation By Investing.com - Investing.com Nigeria
Windtree Therapeutics announces board member resignation - Investing.com Australia
Windtree Therapeutics (WINT) Advances Clinical and Strategic Ini - GuruFocus
Windtree Therapeutics Reports 2024 Progress and Strategy Shift - TipRanks
WINDTREE THERAPEUTICS INC /DE/ SEC 10-K Report - TradingView
Windtree Therapeutics reports FY24 EPS ($104.35) vs. ($4,718.84) last year - TipRanks
Windtree Therapeutics sees cash runway through April - TipRanks
Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates - TradingView
Company Secures Additional Funding to Sustain Operations Through April 2025 | WINT Stock News - GuruFocus
Windtree Slashes Losses by $18.5M as Cardiogenic Shock Drug Shows Promise - Stock Titan
Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Significant Growth in Short Interest - Defense World
Windtree Therapeutics Issues Convertible Notes to Raise $250,000 - Investing.com Australia
Windtree Therapeutics (WINT) to Release Earnings on Tuesday - Defense World
Evofem Biosciences Inks Amendment with Windtree for PHEXXI Supply - Investing.com
Windtree Therapeutics Delays Annual Report Filing - TipRanks
Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Large Decline in Short Interest - Defense World
Windtree Therapeutics Regains Nasdaq Compliance - MSN
Windtree Therapeutics Announces Reverse Stock Split to Maintain Nasdaq Compliance - MSN
Windtree reports positive Phase 2b study on heart failure therapy - MSN
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cos - GuruFocus
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics - Marketscreener.com
US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert - Benzinga
Windtree Therapeutics Inc. (WINT) Soars 14.63% on Nasdaq Compliance - AInvest
Massive 60% Cost Cut: How PHEXXI's New Deal Transforms Global Contraceptive Access - Stock Titan
Windtree Therapeutics IncOn March 20, Entered License And Supply Agreement With Evofem BiosciencesSEC Filing - MarketScreener
Windtree Therapeutics Inc Stock (WINT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):